{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360016866459048832.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1177/135965350901400512"}},{"identifier":{"@type":"URI","@value":"https://journals.sagepub.com/doi/pdf/10.1177/135965350901400512"}}],"dc:title":[{"@value":"Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec><jats:title>Background</jats:title><jats:p> The rate of cytomegalovirus (CMV) mutations conferring ganciclovir resistance was assessed in a trial comparing intravenous ganciclovir and oral valganciclovir for treatment of CMV disease in solid organ transplant (SOT) recipients. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> Viral genes ( UL97 and UL54) conferring ganciclovir resistance were amplified and sequenced from blood samples collected at days 0 (before therapy), 21 (end of induction) and 49 (end of maintenance). </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> The overall risk of developing a confirmed or probable ganciclovir resistance mutation during treatment was similar for patients treated with ganciclovir (2.3%) and valganciclovir (3.6%; P=0.51). A persistent viral load at day 21 was associated with a significant risk of ganciclovir resistance by day 49 (odds ratio 11.83; P=0.022). In multivariate analyses, presence of a confirmed ganciclovir resistance mutation was independently associated with virological failure (viral load ≥600 copies/ml) at days 21 and 49. One-third (3/9) of patients with confirmed CMV resistance mutations had recurrent CMV disease. The plasma half-life of confirmed ganciclovir-resistant UL97 mutants was significantly longer than that of wild-type strains, polymorphic variants and strains with mutations of unknown significance ( P=0.045). Multiple UL54 mutations of unknown significance were found in clinical strains. Viral kinetic analysis of these latter strains revealed no effect (negative or positive) on in vivo viral fitness. </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> Treatment with oral valganciclovir or intravenous ganciclovir results in similar and low rates of resistance mutations in SOT recipients. Patients with drug-resistant CMV strains often have virological failure and might have unfavourable clinical outcomes. </jats:p></jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380016866459048833","@type":"Researcher","foaf:name":[{"@value":"Guy Boivin"}],"jpcoar:affiliationName":[{"@value":"Infectious Disease Research Center of the Centre hospitalier universitaire de Québec, Québec City, QC, Canada"},{"@value":"Laval University, Québec City, QC, Canada"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459048707","@type":"Researcher","foaf:name":[{"@value":"Nathalie Goyette"}],"jpcoar:affiliationName":[{"@value":"Infectious Disease Research Center of the Centre hospitalier universitaire de Québec, Québec City, QC, Canada"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459048835","@type":"Researcher","foaf:name":[{"@value":"Halvor Rollag"}],"jpcoar:affiliationName":[{"@value":"Institute of Microbiology, University of Oslo, Oslo, Norway"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459048832","@type":"Researcher","foaf:name":[{"@value":"Alan G Jardine"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, University of Glasgow, Glasgow, UK"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459048705","@type":"Researcher","foaf:name":[{"@value":"Mark D Pescovitz"}],"jpcoar:affiliationName":[{"@value":"Department of Surgery and Microbiology, Indiana University, Indianapolis, IN, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459048704","@type":"Researcher","foaf:name":[{"@value":"Anders Asberg"}],"jpcoar:affiliationName":[{"@value":"Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459048834","@type":"Researcher","foaf:name":[{"@value":"Jane Ives"}],"jpcoar:affiliationName":[{"@value":"Roche Products Ltd, Welwyn Garden City, UK"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459048708","@type":"Researcher","foaf:name":[{"@value":"Anders Hartmann"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, Rikshospitalet-Radiumhospitalet Medical Centre, University of Oslo, Olso, Norway"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459048706","@type":"Researcher","foaf:name":[{"@value":"Atul Humar"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, University of Alberta, Edmonton, AB, Canada"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13596535"},{"@type":"EISSN","@value":"20402058"}],"prism:publicationName":[{"@value":"Antiviral Therapy"}],"dc:publisher":[{"@value":"SAGE Publications"}],"prism:publicationDate":"2009-07","prism:volume":"14","prism:number":"5","prism:startingPage":"697","prism:endingPage":"704"},"reviewed":"false","dc:rights":["https://journals.sagepub.com/page/policies/text-and-data-mining-license"],"url":[{"@id":"https://journals.sagepub.com/doi/pdf/10.1177/135965350901400512"}],"createdAt":"2022-04-14","modifiedAt":"2025-03-02","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360576118760783360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1177/135965350901400512"},{"@type":"CROSSREF","@value":"10.1038/s41598-021-93168-x_references_DOI_I6G1IiCLFSYtvRhGyW97WR2DZjO"}]}